Chief Scientific Officer
Dr. Robert Andrews is an experienced strategic and tactical manager and researcher in organic and medicinal chemistry, drug design and discovery, and pharmaceutical development, providing solutions to difficult problems in these fields.
He has over 30 years of experience in large and small companies in progressing multiple small molecule drug candidates via experimental work and management through the successive phases of design, lead discovery, lead optimization, drug substance and drug product production, regulatory submission, and investigational product production for clinical development.
His efforts have led to 18 new chemical entities entering human clinical trials in the metabolic disease, CNS, cardiovascular disease, urology, inflammation/immunology, and ophthalmology therapeutic categories.
Inventions and scientific discoveries are exemplified in multiple issued patents, presentations, and publications.
Dr. Andrews earned a Ph.D. degree in chemistry at the University of South Carolina studying under James A. Marshall, and was awarded a NIH postdoctoral fellowship to work at Colorado State University with Albert I. Meyers.
Rob joined Glaxo Research Institute in 1988, working primarily in immunology/inflammation, and departed in 2001 to join TransTech Pharma to direct chemistry for discovery and early development of drugs in numerous therapeutic areas.
Efforts at TransTech Pharma and its successor company vTv Therapeutics resulted in, among others, the advanced clinical candidates TTP488 (azeliragon) for Alzheimer's disease and TTP399 for type 1 and type 2 diabetes.